[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"transplant-complication-rejection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:transplant-complication-rejection":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,55],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":35,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":44,"lastUpdatePostDateStruct":45,"startDateStruct":48,"completionDateStruct":50,"leadSponsor":52,"locationsCount":4},"100512344","liver-transplantation-after-ex-vivo-liver-perfusion-100512344",false,"NCT05951231","Liver Transplantation After ex Vivo Liver Perfusion","Liver Transplantation After ex Vivo Liver Perfusion - The EVOLVE Study","EVOLVE","Inclusion Criteria:\n\n* Signed informed consent\n* ≥ 18 years\n* Indication for liver transplantation (one criteria must be met):\n* Colorectal cancer patients who have received 1st and 2nd line chemotherapy where the treatment has been stopped due to progression or toxicity and the patient is not eligible for SECA-2 (Survival Following Liver Transplantation for Patients With Nonresectable Liver-only Colorectal Metastases) study.\n* Hepatocellular carcinoma patients who are not suitable for standard liver transplantation, liver resection or local treatment (Transarterial Chemoembolisation or Selective internal radiotherapy). The patients must have progression or intolerance (toxicity) for immune checkpoint inhibitors or 1st line treatment.\n* Cholangiocarcinoma patients who have progression or intolerance to first-line chemotherapy.\n* Benign liver disease with urgent need for transplantation within months, but no regular graft is available.\n* Life expectancy ≤ 6 months\n* Willing, able and expected cooperation to attend follow-up examinations\n* Patients who have a need for liver transplantation but cannot participate in other transplant studies or participation in another clinical trial with randomization to liver transplantation.\n\nFor malignant disease the following criteria must be met:\n\n* Good performance status assessed at the discretion of the treating physician.\n* ECOG (Eastern Cooperative Oncology Group) 0 or 1\n* Satisfactory blood tests\n\n  * Hemoglobin \\>8 g\u002Fdl\n  * Neutrophiles \\>1.0 (after any Granulocyte colony-stimulating factor)\n  * Platelets \\>75\n  * Bilirubin \\\u003C1.5 x upper normal level\n  * ASAT (Aspartate aminotransferase), ALAT (alanine aminotransferase) \\\u003C5 x upper normal level\n  * Albumin above lower normal level.\n\nExclusion Criteria:\n\n* Already listed for ordinary Ltx with expectance of getting offered a regular liver graft within a reasonable time-frame.\n* Patients included in the control arm of the SECA-3 study or the Excalibur studies except for the Ltx arm of the Excalibur I study.\n* Mental conditions rendering the subject incapable to understand the nature, scope, and consequences of the trial.\n* Any reason why, in the opinion of the investigator, the patient should not participate.","ALL","18 Years","100 Years",{"count":21,"type":22},22,"ESTIMATED","INTERVENTIONAL",[25],"NA","Today, it is difficult to predict liver function after transplantation and therefore livers where poor function is assumed (marginal livers) become discarded. The study aim is to increase the number of available donor livers, especially for liver cancer patients, by pre-treating and testing marginal ones (extended criteria donor (ECD) livers) liver on a liver perfusion machine. A liver perfusion machine can simulate liver transplantation and enables functional\u002Fquality testing before transplantation. The machine will hopefully also make marginal livers more functional by reducing ischemia- \\& reperfusion injury. A marginal donor liver is perfused ex situ with oxygenated blood from a blood donor on a machine. The liver can be tested here for function using internationally recognized criteria. At the same time, the investigators will carry out analyzes with microdialysis which can give a better picture of organ function and damage. Additionally, various samples of the liver and perfusate will be collected. Liver that achieves criteria for transplantation will be offered to the recipient.",[28,29,30,31,32,33,34],"Liver Transplant; Complications","Transplant; Failure, Liver","Transplant Dysfunction","Transplant; Complication, Rejection","Transplant","Liver Metastases","Liver Cancer",[36,37,38,39,40,41,42],"Liver","Transplantation","Perfusion","Dual-end-ischemic Hypothermic Oxygenated Perfusion","Normothermic Machine Perfusion","Controlled Oxygenated Rewarming","Microdialysis","NOT_YET_RECRUITING","2023-10-31",{"date":46,"type":47},"2023-11-01","ACTUAL",{"date":49,"type":22},"2024-02",{"date":51,"type":22},"2029-02",{"name":53,"class":54},"Oslo University Hospital","OTHER",{"id":56,"slug":57,"hasResults":11,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":60,"eligibilityCriteria":61,"healthyVolunteers":11,"sex":17,"minAge":62,"maxAge":4,"enrollmentInfo":63,"targetDuration":4,"studyType":65,"phases":4,"briefSummary":66,"conditions":67,"keywords":4,"overallStatus":43,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":4},"100400576","mechanistic-evaluation-of-treatments-for-acute-antibody-mediated-rejection-of-the-kidney-transplant-100400576","NCT04496037","Mechanistic Evaluation of Treatments for Acute Antibody-Mediated Rejection of the Kidney Transplant","MOT-AMR","Inclusion Criteria:\n\nAll patients enrolled in TAR:GET-1 Signed informed consent prior to any study specific procedures.\n\nExclusion Criteria:\n\nNone","5 Years",{"count":64,"type":22},170,"OBSERVATIONAL","The best treatment for kidney failure is a kidney transplant, but a transplanted kidney only works for about 10 to 15 years on average. One of the reasons that a transplanted kidney can stop working is that the body develops antibodies against it. Antibodies are proteins produced by the body to fight infections. They play a vital role in dealing with infection but in some transplant patients they can 'fight' the organ, meaning it could stop working. This is called acute antibody-mediated rejection (AAMR). A patient experiencing AAMR can be treated to extend the life of the transplanted kidney, but the chances of the kidney still working 4 years later are reduced. There is currently a clinical trial for UK kidney transplant patients who develop AAMR, called TAR:GET-1. Patients participating in TAR:GET-1 will either receive the standard treatment that is currently given in this situation, or the standard treatment with the addition of rituximab. TAR:GET-1 will answer the question: does adding rituximab to standard treatment lengthen the life of a kidney transplant? A second, sub-study is being proposed of the patients enrolled in TAR:GET-1, that will use the existing blood and biopsy samples already taken during TAR:GET-1 plus an optional extra biopsy of the kidney transplant, to improve our understanding of how the treatments of AAMR work. Patients enrolled in TAR:GET-1 will have had a blood test and biopsy of the transplanted kidney to establish the diagnosis of AAMR. They will also have had further blood tests after treatment, and may also have further biopsies taken if their clinician needs these as part of normal care. Material left over in these samples can be used to analyse how treatment works. In addition, patients will be asked if they agree to an extra biopsy of the transplanted kidney 6 months after the treatment begins. These samples will be analysed at a deeper level than would normally be done, looking at the antibodies and biopsies in detail to answer 2 key questions: 1) Can the unique characteristics noted in an individual patient's antibodies and biopsy predict whether a kidney transplant will be lost as a result of AAMR?; 2) Can we tell treatment is working by looking at the changes in a patient's antibodies and biopsies before and after treatment? The answers to these questions will help us understand AAMR and how its treatments work, and potentially improve our ability to select the right treatment for the right patients.",[31],"2020-07-29",{"date":70,"type":47},"2020-08-03",{"date":72,"type":22},"2020-09-01",{"date":74,"type":22},"2028-08-31",{"name":76,"class":54},"Imperial College London"]